Table 2.
Compound | Structure | Asoa (μM; 95% CI) | Amaxb (%; 95% CI) | MPOc | LLEd |
---|---|---|---|---|---|
4 | 39.4 (27 to 57.4) |
430.3 (402.9 to 459.6) |
4 | 7.07 | |
(rac)-9a | 5.1 (1.7 to 14.2) |
197 (177.5 to 222.8) |
4.9 | N/A | |
9b | Inactive | Inactive | N/A | N/A | |
9c | Inactive | Inactive | N/A | N/A | |
9d | 6.3 (4.3 to 9.2) |
252 (238 to 267) |
4.9 | 5.41 | |
9e | 1.0 (0.16 to 4.4) |
132 (122.5 to 143.6) |
4.9 | 6.19 | |
9f | 13.6 (10.1 to 18.2) |
323.7 (310.3 to 337.9) |
5 | 3.87 | |
9g | 25.2 (19.6 to 32.4) |
339.8 (325.4 to 355.4) |
5 | 3.61 | |
10a | 4.4 (1.7 to 11) |
210.9 (191.7 to 231.9) |
5 | 4.58 | |
10b | 6.3 (3.8 to 10.7) |
197.5 (184.9 to 214.8) |
5 | 4.42 | |
10c | 4.2 (3.17 to 5.6) |
264 (256.3 to 272.6) |
5 | 4.60 | |
10d | 15.37 (10.9 to 21.5) |
343 (325.2 to 363.5) |
5 | 4.04 | |
(rac)-10c/d | 29.9 (23.5 to 38.1) |
370.6 (354.6 to 388.0) |
5 | N/A | |
11a | 7.0 (4.9 to 9.9) |
281.2 (266.7 to 297.1) |
4.9 | 5.07 | |
11b | 6.2 (4.5 to 8.5) |
288.3 (274.3 to 303.3) |
4.9 | 5.12 | |
(rac)-11a/b | 5.8 (3.3 to 10.1) |
349 (322.8 to 377.2) |
4.9 | N/A |
Half maximal activation concentration. Values are presented as the mean of n = 4 experiments with 95% confidence intervals (CIs) in parentheses.
Maximum % activation achieved. Values are presented as the mean of n = 4 experiments with 95% confidence intervals (CIs) in parentheses.
Multiparameter optimization.
Ligand-lipophilicity efficiency.
Not applicable.